Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
| ▸ | RXRB | P28702 | 2/20 | 0.37 |
| ▸ | RXRG | P48443 | 2/20 | 0.37 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.34 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18051409 | 0.88 | NOTUM (0.48) | IDO1IKBKBKDM1ARXRARXRB | |
| SCHEMBL99662 | 0.84 | IDO1 (0.59) | IDO1IKBKBKDM1ACTSSCTSK | |
| SCHEMBL1763375 | 0.82 | KIF11 (0.47) | IDO1KDM1AF2RL3NOTUMKDM4E | |
| SCHEMBL25538453 | 0.82 | CYP11B2 (0.42) | IDO1PIM1 | |
| SCHEMBL26128744 | 0.81 | IDO1 (0.33) | IDO1IKBKBS1PR1KDM4E | |
| SCHEMBL28313237 | 0.79 | — | — | |
| SCHEMBL14326107 | 0.77 | KDM4E (0.35) | RXRARXRBRXRGS1PR1S1PR3 | |
| SCHEMBL10581858 | 0.77 | IL1B (0.36) | NOTUMKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL3366573 | 0.75 | SCN9A (0.46) | NOTUM | |
| SCHEMBL16766999 | 0.71 | LMNA (0.36) | IDO1NOTUMMAPK1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024175804-A1 | NUCLEAR TRANSPORT MODULATORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-08-29 | — | — | WO | disclosed |
| CN-115197160-A | Heterocyclic compounds | 武田药品工业株式会社 | 2022-10-18 | — | — | CN | disclosed |
| CN-107108506-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-06-21 | — | — | CN | disclosed |
| US-20210340114-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-04 | — | — | US | disclosed |
| US-20210340114-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-04 | — | — | US | disclosed |
| EP-3848353-A1 | MEDICAMENTS FOR THE TREATMENT OF OPHTHALMIC DISEASES | Takeda Pharmaceutical Company Limited (JP) | 2021-07-14 | — | — | EP | disclosed |
| US-10975043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-13 | — | — | US | disclosed |
| US-10975043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-13 | — | — | US | disclosed |
| EP-3210973-B1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF OPHTHALMIC DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-12-02 | — | — | EP | disclosed |
| US-20200157062-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-21 | — | — | US | disclosed |
| US-10544111-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-28 | — | — | US | disclosed |
| US-10544111-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-28 | — | — | US | disclosed |
| EP-2736883-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20190119225-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-25 | — | — | US | disclosed |
| US-20190119225-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-25 | — | — | US | disclosed |
| US-20180237404-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-23 | — | — | US | disclosed |
| EP-3210973-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-20170137430-A1 | Nuclear Transport Modulators And Uses Thereof | KARYOPHARM THERAPEUTICS INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-9428490-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2016-08-30 | — | — | US | disclosed |
| WO-2013019561-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119225-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RARA | IDO1 4763/4885IKBKB 926/4885KDM1A 3499/4885 |
| US-20170137430-A1 | Nuclear Transport Modulators And Uses Thereof | XPO1, XPO5, XPOT | IDO1 4080/4885IKBKB 236/4885KDM1A 2670/4885 |
| US-20210340114-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RARA | IDO1 4763/4885IKBKB 926/4885KDM1A 3499/4885 |
| US-20180237404-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RARA | IDO1 4763/4885IKBKB 926/4885KDM1A 3499/4885 |
| US-10975043-B2 | Heterocyclic compound | RBP4, RBP1, RARA | IDO1 4763/4885IKBKB 926/4885KDM1A 3499/4885 |
| US-10544111-B2 | Heterocyclic compound | RBP4, RBP1, RARA | IDO1 4763/4885IKBKB 926/4885KDM1A 3499/4885 |
| US-20200157062-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RARA | IDO1 4763/4885IKBKB 926/4885KDM1A 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.